Genmab Reports $3B in DARZALEX Sales for Q3 2024, Royalties Continue to Climb
Portfolio Pulse from Benzinga Newsdesk
Genmab A/S reported $3 billion in DARZALEX sales for Q3 2024, with royalties from these sales continuing to rise. The sales were reported by Johnson & Johnson, with $1.684 billion in the U.S. and $1.332 billion internationally. Genmab receives royalties from these sales under a license agreement with Janssen.

October 15, 2024 | 10:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab A/S reported strong Q3 2024 sales of DARZALEX, totaling $3 billion, with significant royalties from these sales. This indicates robust demand and financial performance.
The reported $3 billion in sales for DARZALEX, a key product for Genmab, suggests strong market demand and financial health. The increase in royalties further supports a positive outlook for Genmab's revenue stream.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90